Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6
Online ISSN 1827-1898
Guillaume SCHURTZ 1, Christophe BAUTERS 1, 2, 3, Gregory DUCROCQ 4, 5, Nicolas LAMBLIN 1, 2, 3, Gilles LEMESLE 1, 2
1 Centre Hémodynamique et USIC, Institut CardioPulmonaire, Centre Hospitalier Régional et Universitaire de Lille, Lille, France; 2 Faculté de Médecine de l’Université de Lille, Lille, France; 3 Inserm U1167, Institut Pasteur de Lille, Lille, France; 4 Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France; 5 FACT, DHU FIRE, Université Paris-Diderot, Inserm U1148, Sorbonne Paris-Cité, France
Antithrombotic management of outpatients with stable coronary artery disease (CAD) who also have an indication for long-term oral anticoagulation (OAC) is critical in daily practice since these patients – firstly, are frequent – and secondly, have shown a high risk of both ischaemic events and bleeding as compared to patients without OAC. For now, guidelines recommend that most of such patients should be treated with OAC alone (without any antiplatelet therapy) after 12 months of stability even when a stent has been implanted. Robust data are however very sparse and level of evidence very low to support such a strategy. The goal of the present manuscript is to review all available evidences to help physician’s choices in this specific context and to highlight remaining questions that should be addressed by new studies in the next future.